Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study

Autor: Mikkel Pejstrup Agger, Else Rubæk Danielsen, Marcus Schultz Carstensen, N. Mai Nguyen, Maibritt Horning, Mark Alexander Henney, Christopher Boe Ravn Jensen, Anders Ohlhues Baandrup, Troels Wesenberg Kjær, Kristoffer Hougaard Madsen, Kamilla Miskowiak, Paul Michael Petersen, Peter Høgh

Publikováno v: Agger, M P, Danielsen, E R, Carstensen, M S, Nguyen, N M, Horning, M, Henney, M A, Jensen, C B R, Baandrup, A O, Kjaer, T W, Madsen, K H, Miskowiak, K W, Petersen, P M & Høgh, P 2023, ' Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease : A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study ', Journal of Alzheimer's Disease, vol. 92, no. 2, pp. 653-665 . https://doi.org/10.3233/JAD-221238

Background: Recent studies suggested induction of 40 Hz neural activity as a potential treatment for Alzheimer’s disease (AD). However, prolonged exposure to flickering light raises adherence and safety concerns, encouraging investigation of tolera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a562e9f39e60247fad7997f1361a01ce
https://doi.org/10.3233/jad-221238